Guggenheim Securities may act as agent or principal and is entitled to a 3.0% commission. The last reported sale price on August 7, 2026 was $42.39 per share, and the supplement puts dilution to new buyers at $37.68 per share.
Cogent Biosciences closed a $230,000,000 offering of 1.625% convertible notes due 2031 on November 18, 2025, including the full over-allotment option. The 8-K names no underwriters, and the company's 2024 annual report showed operating cash use of $207.8 million that year.
Cogent drew $50 million of a term loan facility of up to $400 million from SLR credit funds on June 11, 2025. Most of the rest depends on pivotal trial results and a launch the company expects in 2026, and the debt falls due in 2030.
The amount is what remains under a $75,000,000 sales agreement with Guggenheim Securities after $25,000,000 was sold earlier. Dilution to new buyers at the May 2 price is $4.05 per share, and the company has recorded net losses in every year since it was founded.
Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $181.2 million, plus short-term investments of $611.1 million, $792.3 million in all.
Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice.
Questions about Cogent Biosciences
Has Cogent Biosciences raised money recently?
Our latest story on this, dated Aug 10, 2026: "Cogent Biosciences files for up to $400,000,000 at-the-market stock sales". The story links the filing or release it is based on. Read the story.
Has Cogent Biosciences sold convertible notes?
Our latest story on this, dated Nov 18, 2025: "Cogent Biosciences completes $230,000,000 offering of 1.625% convertible notes due 2031". The story links the filing or release it is based on. Read the story.
What is the ticker symbol of Cogent Biosciences?
Cogent Biosciences, Inc. trades under the ticker COGT on NASDAQ.
Where is Cogent Biosciences listed?
Cogent Biosciences, Inc. is listed on NASDAQ.
What is the SEC CIK of Cogent Biosciences?
The SEC Central Index Key (CIK) for Cogent Biosciences, Inc. is 1622229. Its filings are on SEC EDGAR.
How many shares does Cogent Biosciences have outstanding?
173,524,982 shares as of 2026-08-06, per the cover page of its 10-Q filed 2026-08-10.
Which country or territory is Cogent Biosciences listed under?
Our directory records Cogent Biosciences, Inc. under United States.
What does Cogent Biosciences do?
Our directory classifies Cogent Biosciences, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.
What is the ISIN of Cogent Biosciences?
The ISIN recorded for Cogent Biosciences, Inc. is US19240Q2012.
Does aibio.space cover Cogent Biosciences?
aibio.space lists Cogent Biosciences, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
Where is Cogent Biosciences incorporated?
SEC records list its state or country of incorporation as DE.
Is Cogent Biosciences profitable?
Cogent Biosciences, Inc. reported a net loss of $328.9 million for the fiscal year ended Dec 31, 2025, and used $264.4 million of cash in operations, per its annual report to the SEC.
How much does Cogent Biosciences spend on research and development?
$269.8 million in the fiscal year ended Dec 31, 2025, per its annual report.
How much cash does Cogent Biosciences have?
$792.3 million in cash and short-term investments at Jun 30, 2026, per its 10-Q.
What is the latest Cogent Biosciences (COGT) stock news?
Our latest story on Cogent Biosciences, dated Aug 10, 2026: "Cogent Biosciences files for up to $400,000,000 at-the-market stock sales". Guggenheim Securities may act as agent or principal and is entitled to a 3.0% commission. The last reported sale price on August 7, 2026 was $42.39 per share, and the supplement puts dilution to new buyers at $37.68 per share. Source.
Investor discussion: Cogent Biosciences
Members talk about Cogent Biosciences (COGT). Reader posts, not aibio.space reporting, and not investment advice.
Rules
Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
Say whether you hold the stock. Every post states long, short or no position.
No paid or sponsored posts. Do not post for anyone who pays or rewards you.
No buy or sell calls and no price targets.
No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
No personal details and no spam. No links at all for your first 7 days as a member.
Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.
Capital-markets timeline
Financings, listing notices, splits, legal actions and other investor events at Cogent Biosciences, newest first. Each line links the filing it comes from.
Set up an at-the-market program to sell shares over time. SEC Form 424B5. Source
Stock chart
Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open NASDAQ:COGT on TradingView.
SEC filings and registration
SEC name
Cogent Biosciences, Inc.
CIK
1622229
Industry (SIC)
Pharmaceutical Preparations (2834)
US tickers
COGT (Nasdaq)
State or country of incorporation
DE
Fiscal year ends
December 31
Filer category
Large accelerated filer
Business address
180 THIRD AVENUE, WALTHAM, MA
Phone
617-945-5576
Shares outstanding
173,524,982 as of 2026-08-06 (10-Q filed 2026-08-10)
Former names
Unum Therapeutics Inc.; Unum Therapeutics, Inc.
Recent filings (8-K and 6-K are the company's own announcements)
Source: SEC EDGAR, retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices.
Listing details
Cogent Biosciences, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker COGT, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.
Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.
Published and maintained by aibio.space. Not investment advice. How we work.
Who manages this pageThis page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio